Phase II study of imatinib mesylate in chemotherapy refractory germ cell tumors expressing KIT

被引:83
作者
Einhorn, LH
Brames, MJ
Heinrich, MC
Corless, CL
Madani, A
机构
[1] Indiana Univ, Dept Med, Div Hematol Oncol, Indianapolis, IN USA
[2] Walther Canc Inst, Indianapolis, IN USA
[3] Oregon Hlth & Sci Univ, Inst Canc, Dept Med, Div Hematol Oncol, Portland, OR USA
[4] Portland VA Med Ctr, Portland, OR USA
[5] Oregon Hlth & Sci Univ, Dept Pathol, Portland, OR USA
[6] Hematol & Oncol Assoc So Michigan, Jackson, MI USA
来源
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 2006年 / 29卷 / 01期
关键词
KIT; germ cell tumor; imatinib;
D O I
10.1097/01.coc.0000195086.47548.ef
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: This phase II study was conducted to determine the activity of imatinib (gleevec) in heavily pretreated patients with KIT-positive metastatic germ cell tumor. Materials and Methods: From June 2002 through April 2005, 18 patients with refractory germ cell tumors were tested for KIT expression by immunohistochemistry. All patients screened were deemed to be incurable with further standard chemotherapy or surgery. Six patients were eligible and treated with imatinib 600 mg/d orally. Results: There were no complete or partial remissions. Five of 6 patients had progressive disease and 1 patient had stable disease with a > 50% decline in serum alpha-fetoprotein for 3 months before developing further progression. Conclusion: In this small sample size, there was no evidence of significant antitumor activity of imatinib in patients with KIT-positive refractory germ cell tumors.
引用
收藏
页码:12 / 13
页数:2
相关论文
共 15 条
[1]  
Bedano PM, 2005, J CLIN ONCOL, V23, p384S
[2]   High-dose chemotherapy as initial salvage chemotherapy in patients with relapsed testicular cancer [J].
Bhatia, S ;
Abonour, R ;
Porcu, P ;
Seshadri, R ;
Nichols, CR ;
Cornetta, K ;
Einhorn, LH .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (19) :3346-3351
[3]   Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors [J].
Demetri, GD ;
von Mehren, M ;
Blanke, CD ;
Van den Abbeele, AD ;
Eisenberg, B ;
Roberts, PJ ;
Heinrich, MC ;
Tuveson, DA ;
Singer, S ;
Janicek, M ;
Fletcher, JA ;
Silverman, SG ;
Silberman, SL ;
Capdeville, R ;
Kiese, B ;
Peng, B ;
Dimitrijevic, S ;
Druker, BJ ;
Corless, C ;
Fletcher, CDM ;
Joensuu, H .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (07) :472-480
[4]   Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. [J].
Druker, BJ ;
Talpaz, M ;
Resta, DJ ;
Peng, B ;
Buchdunger, E ;
Ford, JM ;
Lydon, NB ;
Kantarjian, H ;
Capdeville, R ;
Ohno-Jones, S ;
Sawyers, CL .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1031-1037
[5]   A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study [J].
Dy, GK ;
Miller, AA ;
Mandrekar, SJ ;
Aubry, MC ;
Langdon, RM ;
Morton, RF ;
Schild, SE ;
Jett, JR ;
Adjei, AA .
ANNALS OF ONCOLOGY, 2005, 16 (11) :1811-1816
[6]   TREATMENT OF TESTICULAR CANCER - A NEW AND IMPROVED MODEL [J].
EINHORN, LH .
JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (11) :1777-1781
[7]   Curing metastatic testicular cancer [J].
Einhorn, LH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (07) :4592-4595
[8]   Update on late relapse of germ cell tumor: A clinical and molecular analysis [J].
George, DW ;
Foster, RS ;
Hromas, RA ;
RObertson, KA ;
Vance, GH ;
Ulbright, TM ;
Gobbett, TA ;
Heiber, DJ ;
Heerema, NA ;
Ramsey, HC ;
Thurston, VC ;
Jung, SH ;
Shen, JZ ;
Finch, DE ;
Kelley, MP ;
Einhorn, LH .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (01) :113-122
[9]   Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor [J].
Heinrich, MC ;
Corless, CL ;
Demetri, GD ;
Blanke, CD ;
von Mehren, M ;
Joensuu, H ;
McGreevey, LS ;
Chen, CJ ;
Van den Abbeele, AD ;
Druker, BJ ;
Kiese, B ;
Eisenberg, B ;
Roberts, PJ ;
Singer, S ;
Fletcher, CDM ;
Silberman, S ;
Dimitrijevic, S ;
Fletcher, JA .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (23) :4342-4349
[10]   Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897): A trial of the eastern cooperative oncology group [J].
Hinton, S ;
Catalano, P ;
Einhorn, LH ;
Leohrer, PJ ;
Kuzel, T ;
Vaughn, D ;
Wilding, G .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (07) :1859-1863